Compare Amphastar Pharmaceuticals Inc (AMPH) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Liberty Global Ltd Class C — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Liberty Global Ltd Class C trades at $9.98 (market cap $3.48B). The key difference: Liberty Global Ltd Class C is far larger — about 4× Amphastar Pharmaceuticals Inc's market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| AMPH | LBTYK | |
|---|---|---|
Market Cap | $863.95M | $3.48B |
Sector | Health | Technology |
52-Week High | $30.81 | $12.67 |
52-Week Low | $16.87 | $9.59 |
Enterprise Value | $1.26B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
LBTYK trades at $10.24, down 2.38% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.14 billion in 2025, though operating cash flow remains positive at $1.21 billion. Recent news highlights the completion of the VodafoneZiggo buyout and preparations for a 2027 Ziggo Group listing, a key strategic move.
Despite deep losses, the stock appears undervalued on price-to-sales (0.7) and price-to-book (0.37) metrics. Analyst sentiment is strongly bullish (69% buy ratings), seeing upside from asset monetization and the Ziggo spin-off. Key risks include persistent negative margins and execution of the separation plan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
